drug

XMAB541

1 story · latest Aug 5, 2026

Status: Investigational
Trials: 2 registered trials in coverage

Relationships

Developed by Xencor, Inc.

Timeline

Xencor reports Q2 2026 results, sets ESMO date for XmAb819 kidney cancer data

Aug 5Quarterly updateXencor, Inc.XMAB819

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.